RE:TheranosticsThis is exactly what I am talking about relentlessly here, but for prostate cancer. Personnally, I was talking about neuroendocrine cancers, which was the cancer for which the first PDCs developped with radioisotopes. In this case it's a more recent development in prostate cancer. It uses a tripeptide linked to a non peptidic part. This peptide based molecule has affinity for the PSMA receptor overexpressed in prostate cancer. The rest is the same. They use the DOTA linker to chelate the isotopes. They now have the imaging version with Gallium 68, the therapeutic version with Lutetium 177, and they already do trials with Actinium 225. Wake up Marsolais and Thera!!!!
https://www.researchgate.net/figure/Chemical-structures-of-DOTAGA-FFKSub-KuE-a-first-generation-tracer-upper-and-PSMA_fig3_278788852
Lee430 wrote: Molecular-targeted liquid radiation, is this simular to what jfm1330 has been refering to that Thera could use with the peptide or a completly different new therapy?
https://www.dailybulletin.com/2021/07/24/new-hope-in-the-fight-against-prostate-cancer-we-can-win-this-war/